Abstract:Meng-Ru Zhang, 1, 2, &ast Lin-Lin Fang, 3, &ast Yang Guo, 1 Qin Wang, 1 You-Jie Li, 1 Hong-Fang Sun, 1 Shu-Yang Xie, 1 Yan Liang 1 1 Department of Biochemistry and Molecular Biology, School of Basic Medicine, Binzhou Medical University, YanTai, ShanDong, 264003, People's Republic of China; 2 Department of Clinical Medicine, Binzhou Medical University, YanTai, ShanDong, 264003, People's Republic of China; 3 RemeGen Co., Ltd, YanTai, ShanDong, 264000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Liang; Shu-Yang Xie, Department of Biochemistry and Molecular Biology, School of Basic Medicine, Binzhou Medical University, YanTai, ShanDong, 264003, People's Republic of China, Tel/Fax +86 535 6913335 ; +86 535 6913166, Email ; Cancer immunotherapy has emerged as a novel therapeutic approach against tumors, with immune checkpoint inhibitors (ICIs) making significant clinical practice. The traditional ICIs, PD-1 and PD-L1, augment the cytotoxic function of T cells through the inhibition of tumor immune evasion pathways, ultimately leading to the initiation of an antitumor immune response. However, the clinical implementation of ICIs encounters obstacles stemming from the existence of an immunosuppressive tumor microenvironment and inadequate infiltration of CD8 + T cells. Considerable attention has been directed towards advancing immunogenic cell death (ICD) as a potential solution to counteract tumor cell infiltration and the immunosuppressive tumor microenvironment. This approach holds promise in transforming "cold" tumors into "hot" tumors that exhibit responsiveness to antitumor. By combining ICD with ICIs, a synergistic immune response against tumors can be achieved. However, the combination of ICD inducers and PD-1/PD-L1 inhibitors is hindered by issues such as poor targeting and uncontrolled drug release. An advantageous solution presented by stimulus-responsive nanocarrier is integrating the physicochemical properties of ICD inducers and PD-1/PD-L1 inhibitors, facilitating precise delivery to specific tissues for optimal combination therapy. Moreover, these nanocarriers leverage the distinct features of the tumor microenvironment to accomplish controlled drug release and regulate the kinetics of drug delivery. This article aims to investigate the advancement of stimulus-responsive co-delivery nanocarriers utilizing ICD and PD-1/PD-L1 inhibitors. Special focus is dedicated to exploring the advantages and recent advancements of this system in enabling the combination of ICIs and ICD inducers. The molecular mechanisms of ICD and ICIs are concisely summarized. In conclusion, we examine the potential research prospects and challenges that could greatly enhance immunotherapeutic approaches for cancer treatment. Keywords: antitumor therapy, immunogenic cell death, co-delivery, immune-checkpoint inhibitors, stimulus-responsive nanocarriers Cancer, being a substantial global public-health concern, is projected to 28.4 million cases worldwide by the year 2040. 1 In recent decades, cancer immunotherapy has made noteworthy strides. In recent decades, cancer immunotherapy has made significant progress. Currently, it predominantly focuses on two domains. The first is the activation of key components within the immune system, including cancer vaccines, 2 cytokine therapy, 3 and adoptive T-cell therapy. 4 The second domain involves the suppression of immune-checkpoint molecules, such as immune-checkpoint blocking (ICB). 5,6 Immune-checkpoint molecules refer to the small proteins produced by immune cells in the body that regulate effector function. Tumor cells evade and survive the body's immune system by overactivating immune-checkpoint molecules. Immune-checkpoint inhibitors (ICIs) can prevent the overactivation of immune checkpoint inhibitors, allowing immune cells to eliminate cancer cells. ICIs exert their antitumor effects mainly through PD-1/PD-L1 inhibitors. 7 PD-1/PD-L1 inhibitors include PD-1 antibodies and PD-L1 antibodies, which can bind to PD-1 and PD-L1 respectively, preventing the binding of cancer cells and T cells. Then promoting the T cell-mediated killing and clearance of tumors. However, numerous tumors exhibit a poor response to the use of PD-1/PD-L1 checkpoint inhibitors alone. 8–10 This is due to the fact that the tumors are mostly "cold" tumors, which are manifested as a low immunogenicity of the tumor cells. Furthermore, the immunosuppressive tumor microenvironment (ITM) significantly impedes the infiltration and function of cytotoxic lymphocytes (CTLs), which contributes to sustained tumor growth. Resear -Abstract Truncated-

Improved Cancer Immunochemotherapy Via Optimal Co-Delivery Of Chemotherapeutic And Immunomodulatory Agents

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.

Dual Functional Immunostimulatory Polymeric Prodrug Carrier with Pendent Indoximod for Enhanced Cancer Immunochemotherapy

A Site-Oriented Nanosystem for Active Transcellular Chemo-Immunotherapy to Prevent Tumor Growth and Metastasis

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Nanotechnology-mediated Immunochemotherapy Combined with Docetaxel and PD-L1 Antibody Increase Therapeutic Effects and Decrease Systemic Toxicity.

Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy

Precision Delivery of Dual Immune Inhibitors Loaded Nanomodulator to Reverse Immune Suppression for Combinational Photothermal-Immunotherapy

Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy

Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and Ph Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles

Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer

Spatial Targeting of Tumor-Associated Macrophage and Tumor Cells with a Designer Nanocarrier for Cancer Chemo-Immunotherapy.

Correction to “modular Engineering of Targeted Dual-Drug Nanoassemblies for Cancer Chemoimmunotherapy”

An Efficient Fabrication Approach for Multi-Cancer Responsive Chemoimmuno Co-Delivery Nanoparticles

Novel Cocktail Therapy Based on a Nanocarrier with an Efficient Transcytosis Property Reverses the Dynamically Deteriorating Tumor Microenvironment for Enhanced Immunotherapy